<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675489</url>
  </required_header>
  <id_info>
    <org_study_id>20-01</org_study_id>
    <nct_id>NCT04675489</nct_id>
  </id_info>
  <brief_title>Visual Outcomes After Vivity Toric IOL Implantation</brief_title>
  <official_title>Patient Satisfaction and Visual Outcomes After Bilateral Implantation of a Novel Non-Diffractive Extended Vision Toric Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EVP Eye Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icon Eye Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EVP Eye Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate patient satisfaction after bilateral implantation of&#xD;
      Vivity Toric Extended Vision Intraocular lens and visual outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate and report outcomes including postoperative uncorrected visual acuity,&#xD;
      postoperative best corrected visual acuity, postoperative refractive error, and IOL&#xD;
      rotational stability after Vivity Toric Extended Vision intraocular lens (IOL) implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects to receive bilateral implantation of Vivity Extended Vision Toric Intraocular Lens</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monocular visual acuity at distance</measure>
    <time_frame>4 months</time_frame>
    <description>Monocular uncorrected distance visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binocular visual acuity at distance</measure>
    <time_frame>4 months</time_frame>
    <description>Binocular uncorrected distance visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocular best corrected distance visual acuity</measure>
    <time_frame>4 months</time_frame>
    <description>Monocular best corrected distance visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binocular best corrected distance visual acuity</measure>
    <time_frame>4 months</time_frame>
    <description>Binocular best corrected distance visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocular best distance-corrected intermediate visual acuity</measure>
    <time_frame>4 months</time_frame>
    <description>Monocular best distance-corrected intermediate visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binocular best distance-corrected intermediate visual acuity</measure>
    <time_frame>4 months</time_frame>
    <description>Binocular best distance-corrected intermediate visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocular best distance-corrected near visual acuity</measure>
    <time_frame>4 months</time_frame>
    <description>Monocular best distance-corrected near visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binocular best distance-corrected near visual acuity</measure>
    <time_frame>4 months</time_frame>
    <description>Binocular best distance-corrected near visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual refractive cylinder</measure>
    <time_frame>4 months</time_frame>
    <description>Manifest postoperative refractive cylinder (measured in diopters, with a phoropter) after cataract surgery and IOL implantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Refractive Assessment</condition>
  <arm_group>
    <arm_group_label>Vivity Toric IOL</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cataract that had phacoemulsification and Vivity Toric IOL implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Procedure: Vivity Toric IOL</intervention_name>
    <description>The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.</description>
    <arm_group_label>Vivity Toric IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Calculated lens power within study IOL range of 15.0 diopters to 25.0 diopters and&#xD;
             toric range of T3 to T6&#xD;
&#xD;
          -  Willing and able to comprehend informed consent form and to complete 1 day and 3-4&#xD;
             month postoperative visit&#xD;
&#xD;
          -  Potential postoperative best corrected distance visual acuity of 20/20 or better in&#xD;
             each eye based on medical opinion of investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular pathology or comorbidity that could reduce potential postoperative best&#xD;
             corrected distance visual acuity&#xD;
&#xD;
          -  Ocular trauma or zonular weakness/instability&#xD;
&#xD;
          -  Diagnosis of glaucoma or high-risk glaucoma suspect&#xD;
&#xD;
          -  Previous refractive surgery&#xD;
&#xD;
          -  Unreliable preoperative biometry measurements&#xD;
&#xD;
          -  Severe dry eye or ocular surface disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Fox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icon Eye Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Bosch</last_name>
    <phone>970-205-9555</phone>
    <email>chris.bosch@iconeyecare.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Holt, OD</last_name>
    <phone>970-256-0400</phone>
    <email>james.holt@iconeyecare.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icon Eye Care</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Bosch</last_name>
      <phone>970-205-9555</phone>
      <email>chris.bosch@iconeyecare.com</email>
    </contact>
    <contact_backup>
      <last_name>James Holt, OD</last_name>
      <phone>970-256-0400</phone>
      <email>james.holt@iconeyecare.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Holt, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vivity</keyword>
  <keyword>Extended Vision Toric Intraocular Lens</keyword>
  <keyword>Patient satisfaction and visual outcomes</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

